141 / 1835
What about ABVD needs improving?
•
Bleomycin lung toxicity with ABVD
•
Efficacy of ABVD is decreased in certain subgroups
−
In patients with stage III/IV disease, the 5-year FFS is about
65%
−
In patients >60 years, the 5-year FFS is poor
−
In patients with IPS 3-7, the 5-year FFS is about 65%
•
Long-term tumour control of 70% not good enough
Improve efficacy!